Uttarakhand News Today

Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight

 Breaking News
  • No posts were found

Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight

August 01
09:13 2020
Adrenoleukodystrophy Emerging drugs and Key Players | DelveInsight

DelveInsight Business Research LLP
Adrenoleukodystrophy Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines.

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.


Adrenoleukodystrophy Emerging Therapies


  1. Lenti D: bluebird bio
  2. Leriglitazone: Minoryx Therapeutics, S.L.
  3. MD1003: MedDay Pharmaceuticals
  4. MGTA-456: Magenta Therapeutics
  5. OP-101: Orpheris Inc.
  6. SOM1201: SOM Biotech


Scope of the Report

  • The Adrenoleukodystrophy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Adrenoleukodystrophy across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Adrenoleukodystrophy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Adrenoleukodystrophy research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Adrenoleukodystrophy .


Request for sample pages

Table of contents

1. Report Introduction

2. Adrenoleukodystrophy  

2.1. Overview

2.2. History 

2.3. Adrenoleukodystrophy Symptoms

2.4. Causes


2.6. Adrenoleukodystrophy Diagnosis 

2.6.1. Diagnostic Guidelines

3. Adrenoleukodystrophy  Current Treatment Patterns

3.1. Adrenoleukodystrophy Treatment Guidelines

4. Adrenoleukodystrophy  – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Adrenoleukodystrophy  companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Adrenoleukodystrophy  Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Adrenoleukodystrophy  Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Adrenoleukodystrophy Late Stage Products (Phase-III)

7. Adrenoleukodystrophy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Adrenoleukodystrophy Discontinued Products

13. Adrenoleukodystrophy  Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

14. Adrenoleukodystrophy  Key Companies

15. Adrenoleukodystrophy  Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Adrenoleukodystrophy  Unmet Needs

18. Adrenoleukodystrophy  Future Perspectives

19. Adrenoleukodystrophy  Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles